New Phase 2 Data Show Promise Of Aranesp(R) Treatment For Anemia Of Cancer
Mon, 11 Dec 2006 08:00 AM EST
... Amgen (NASDAQ:AMGN) today announced final results of a 17-week randomized, double-blind, placebo-controlled, Phase 2 study evaluating Aranesp(R) (darbepoetin alfa) administered every four weeks for the treatment of anemia in cancer patients not undergoing chemotherapy and/or myelosuppressive radiotherapy, a condition known as anemia of cancer. [click link for full article] ...
Related Topics
- Darbepoetin alfa
- Anemia
- Data & Statistics
- Data Analysis
- Aplastic Anemia
- Sickle Cell Anemia
- National Data
- Pernicious Anemia
- Iron Deficiency Anemia
- Prostate Cancer
- Sickle Cell
- Treatment
- Kidney Cancer
- Pancreatic Cancer
- Esophageal Cancer
- Stomach Cancer
- Bladder Cancer
- Uterine Cancer
- Clinical Trials
- Cancers

Not Signed In -


